Top Markets
#1 TENDIES TENDIES +59.67%
#2 Threshold Network Threshold Network +58.79%
#3 Cash Cat Cash Cat +21.23%
#4 OSK OSK +15.93%
#5 Magma Finance Magma Finance +13.61%
#6 Falcon Finance Falcon Finance +12.83%
#7 Ape and Pepe Ape and Pepe +12.62%
#8 Kite Kite +11.86%
#9 Maple Finance Maple Finance +11.45%
#10 Asteroid Shiba Asteroid Shiba +9.44%
Coin of the day
TENDIES TENDIES
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Invivyd, Inc. Invivyd, Inc.

Invivyd, Inc.

IVVD
Rang in aandelen #17261
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development... Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Aandeelprijs
$0.8502
Laatst gesynchroniseerd: 2026-09-01
Marktkapitalisatie
$250.47M
Verandering (1 dag)
-10.96%
Verandering (1 jaar)
-17.46%
Land
US
Handel Invivyd, Inc. (IVVD)

Categorie

Healthcare
Winst voor Invivyd, Inc. (IVVD)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Invivyd, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Invivyd, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH